Ecstasy - Long-term effects on the human central nervous system revealed by positron emission tomography

British Journal of Psychiatry

Volumn 175, Issue AUG., 1999, Pages 186-188

  Obrocki, Jost ^a   Buchert, Ralph ^a   Väterlein, Ole ^a   Thomasius, Rainer ^a   Beyer, Wolfgang ^a   Schiemann, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; ARTICLE; CELL ACTIVITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; LONG TERM CARE; MALE; NERVE CELL; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGIC TEST; SEROTONINERGIC SYSTEM;

EID: 0032797403     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.175.2.186     Document Type: Article

References (15)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
2. Andersson, J. L. R. & Thurfjell, L. (1997) Implementation and validation of a fully automatic system for intra-and interindividual registration of PET brain scans. Journal of Computer Assisted Tomography, 21, 136-144.
3. Beck, A. T., Ward, C. H., Mendelson, M., et al (1961) An inventory for measuring depression. Archives of General Psychiatry, 41, 561-567.
4. Derogatis, L. R., Rickels, K. & Rock, A. F. (1976) The SCL-90 and the MMPI: a step in the validation of a new self-report scale. British Journal of Psychiatry, 128, 280-289.
5. First, M. B., Spitzer, R. L., Gibbon, M., et al (1996) Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Clinical Version: User's Guide. Washington, DC: American Psychiatric Press.
6. Green, A. R., Cross, A. J. & Goodwin, G. M. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethaphetamine (MDMA or "ecstasy"). Psychopharmacology, 119, 247-260.
7. Greer, G. & Tolbert, R. (1986) Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs, 18, 319-319.
8. Kleven, M. S., Woolverton, W. L. & Seiden, L. S. (1989) Evidence that both intragastric and subcutaneous administration of methylenedioxymethamphetamine produce serotonin neurotoxicity in rhesus monkeys. Brain Research, 488, 121-125.
9. Lew, R., Sabol, K. E., Chov, C., et al (1996) Methylenedioxymethamphetamine induced serotonin deficits are followed by partial recovery over a 52 week period. Part II: Radioligand binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics, 276, 855-865.
10. McCann, U. D., Ridenour, A., Shaham, Y., et al (1994) Serotonin neurotoxicity after (±) 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"): a controlled study in humans. Neuropsychopharmocology, 10, 129-138.
11. _, Szabo, Z., Scheffel, U., et al (1998) Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurones in human beings. Lancet, 352, 1433-1437.
12. McGuire, P. K., Cope, H. & Fahy, T. A. (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). British Journal of Psychiatry, 165, 391-395.
13. Ricaurte, G. A., Martello, A. L., Katz, J. L., et al (1992) Lasting effects of (±) 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. Journal of Pharmacology and Experimental Therapeutics, 261, 616-622.
14. Sabol, K. E., Lew, R., Richards, R. E., et al (1996) Methylenedioxymethamphetamine induced serotonin deficits are followed by partial recovery over a 52 week period. Part I: Synaptosomal uptake and tissue concentrations. Journal of Pharmacology and Experimental Therapeutics, 276, 846-854.
15. Scheffel, U., Szabo, Z., Mathews, W. B., et al (1998) In vivo detection of short and long term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse, 29, 183-192.